tiprankstipranks
Advertisement
Advertisement

GB:0R1F Stock Latest News

Bristol Myers price target raised to $65 from $60 at HSBC
The FlyBristol Myers price target raised to $65 from $60 at HSBC
2d ago
BMY
Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial
PremiumThe Fly
Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial
4d ago
BMY
Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer
PremiumThe Fly
Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer
9d ago
BMY
EIKN
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
PremiumThe Fly
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
11d ago
BMY
NVS
Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study
PremiumThe Fly
Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study
12d ago
BMY
Trump Trade: Canada rolls out 50% tariffs on U.S. metals
PremiumThe FlyTrump Trade: Canada rolls out 50% tariffs on U.S. metals
16d ago
AA
MT
HHS plans to add FDA deputy roles for technology, drugs, CNBC says
Premium
The Fly
HHS plans to add FDA deputy roles for technology, drugs, CNBC says
17d ago
ABT
BMY
Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target
Premium
Ratings
Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target
23d ago
BMY
Bristol-Myers Squibb: Sell Rating Reiterated as Competitive Pressures Mount; $40 Price Target Unchanged Signaling Further Downside
PremiumRatings
Bristol-Myers Squibb: Sell Rating Reiterated as Competitive Pressures Mount; $40 Price Target Unchanged Signaling Further Downside
26d ago
BMY
Atrium Therapeutics earns $15M milestone payment from Bristol Myers
PremiumThe Fly
Atrium Therapeutics earns $15M milestone payment from Bristol Myers
26d ago
BMY
RNA
Court revives suit against Bristol Myers over delayed drug, Reuters reports
PremiumThe Fly
Court revives suit against Bristol Myers over delayed drug, Reuters reports
26d ago
BMY
UMBF
Bristol Myers’ first CELMoD myeloma therapy granted accelerated FDA approval
PremiumThe Fly
Bristol Myers’ first CELMoD myeloma therapy granted accelerated FDA approval
26d ago
BMY
Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data
PremiumRatingsBalanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data
29d ago
BMY
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
Premium
The Fly
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
1M ago
AZN
BMY
Bristol Myers announces $2.3B campus in Houston, Texas
Premium
The Fly
Bristol Myers announces $2.3B campus in Houston, Texas
1M ago
BMY
Midday Fly By: SpaceX slips, Disney reports earnings beat
PremiumThe Fly
Midday Fly By: SpaceX slips, Disney reports earnings beat
1M ago
BX
MS
Best Buy downgraded, Bristol Myers upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Best Buy downgraded, Bristol Myers upgraded: Wall Street’s top analyst calls
1M ago
AZN
BBY
Bristol Myers upgraded to Buy from Hold at Argus
PremiumThe Fly
Bristol Myers upgraded to Buy from Hold at Argus
1M ago
BMY
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
PremiumThe Fly
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
1M ago
AZN
BMY
Schrodinger announces collaboration, software agreement with Bristol Myers
PremiumThe FlySchrodinger announces collaboration, software agreement with Bristol Myers
1M ago
BMY
SDGR
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
Premium
The Fly
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
1M ago
AZN
BMY
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
Premium
The Fly
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
1M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >